```html

Yungay Disease (High‑Altitude Pulmonary Edema)

Overview

Yungas disease, more commonly called high‑altitude pulmonary edema (HAPE), is a life‑threatening form of non‑cardiogenic pulmonary edema that occurs in otherwise healthy individuals after rapid ascent to high elevations (generally > 2,500 m / 8,200 ft). The condition was first described among travelers in the Yungas region of Bolivia and later named after the tragic 1970 avalanche on the Peruvian mountain town of Yungay, where many victims presented with severe HAPE.

HAPE is part of the spectrum of acute altitude illness, alongside acute mountain sickness (AMS) and high‑altitude cerebral edema (HACE). It typically develops within 2–5 days after ascent, but can appear as early as 12 hours in highly susceptible people.

Who it affects

• Travelers, trekkers, climbers, and workers who ascend rapidly to high altitude.
• People living at sea level who have never acclimatized.
• Individuals with a prior history of HAPE or with certain genetic predispositions (e.g., variants in the EDN1 gene).

Prevalence

• Incidence in military personnel trekking above 3,000 m ranges from 0.2% to 6% depending on ascent speed and prophylaxis use (US Army Med. Res. 2022).
• In civilian trekkers in the Himalayas, reported rates are ~0.3%–0.6% (Mayo Clinic, 2023).
• Most cases occur between 2,500 m and 5,500 m; risk rises dramatically above 4,000 m.

Symptoms

Symptoms of HAPE usually manifest after a few days at altitude and progress quickly. The classic triad includes:

• Dyspnea at rest – a sudden feeling of breathlessness that worsens even while sitting.
• Persistent cough – often dry, later producing frothy or pink‑tinged sputum.
• Decreased exercise tolerance – tasks that were easy at lower elevations become exhausting.

Other frequently reported signs and symptoms:

• Chest tightness or heaviness.
• Rapid breathing (tachypnea) – > 30 breaths/min.
• Rapid heart rate (tachycardia) – > 100 bpm.
• Low‑grade fever (usually <38 °C/100.4 °F).
• Blue‑tinged lips or fingertips (cyanosis).
• Frothy pink sputum indicating alveolar fluid.
• Wheezing or crackles heard on lung auscultation.
• Restlessness, confusion, or altered mental status (indicates progression toward HACE).
• Clubbing of fingernails is not typical for acute HAPE but may be present in chronic high‑altitude residents.

Causes and Risk Factors

Pathophysiology

HAPE results from an abnormal increase in pulmonary capillary pressure caused by uneven hypoxic pulmonary vasoconstriction. At high altitude, low oxygen triggers constriction of pulmonary arteries to redirect blood to better‑ventilated lung regions. In susceptible individuals, this response is exaggerated, leading to:

1. Elevated pulmonary arterial pressure (> 30 mm Hg above baseline).
2. Stress failure of capillaries, allowing fluid to leak into alveoli.
3. Reduced surfactant activity and impaired lymphatic drainage, worsening edema.

Major Risk Factors

• Rapid ascent – gaining > 500 m (1,640 ft) per day above 2,500 m.
• Previous HAPE episode – recurrence risk up to 60% without prophylaxis.
• Cold, high‑altitude environment – low ambient temperature increases vasoconstriction.
• Pre‑existing respiratory disease – asthma, COPD, or recent lower‑respiratory infection.
• Genetic predisposition – polymorphisms in ACE, EDN1, and NOX3 genes.
• Exertion before acclimatization – heavy trekking or climbing within the first 24 h.
• Alcohol or sedative use – depresses ventilatory drive.
• Male sex – slightly higher incidence, possibly due to behavioral factors.

Diagnosis

Diagnosis is primarily clinical, supported by bedside testing and imaging when feasible.

Clinical Evaluation

• History of recent ascent, speed of climb, and symptom timeline.
• Physical examination: tachypnea, tachycardia, bibasilar crackles, cyanosis, and use of accessory muscles.

Diagnostic Tests

• Pulse oximetry – SpO₂ < 80% at rest is highly suggestive (Miller et al., 2021).
• Chest X‑ray – shows patchy, fluffy infiltrates, usually perihilar, without cardiomegaly.
• Arterial blood gas (ABG) – hypoxemia (PaO₂ < 60 mm Hg) with respiratory alkalosis.
• Echocardiography (portable) – elevated pulmonary artery systolic pressure (> 50 mm Hg).
• Chest CT (if available) – ground‑glass opacities confirming alveolar fluid.
• Laboratory studies – generally normal; rule out infection (CBC, CRP).

Differential Diagnosis

Conditions that can mimic HAPE include pneumonia, pneumothorax, bronchial asthma exacerbation, and pulmonary embolism. Lack of fever, normal white‑blood‑cell count, and rapid improvement with descent help differentiate HAPE.

Treatment Options

Immediate management focuses on restoring oxygenation, reducing pulmonary hypertension, and preventing progression.

1. Immediate Descent

Rapid descent of at least 500–1,000 m (1,640–3,280 ft) is the most effective intervention and should be the first step if feasible.

2. Supplemental Oxygen

• Administer > 30 % FiO₂ via non‑rebreather mask; target SpO₂ > 90%.
• Portable oxygen cylinders or concentrators are essential for trekkers.

3. Pharmacologic Therapy

Medication	Mechanism	Typical Dose	Key Notes
Nifedipine (oral or sublingual)	Calcium‑channel blocker; reduces pulmonary artery pressure.	30 mg PO q8h (or 10 mg SL q2h)	First‑line for both prevention and treatment; monitor hypotension.
Phosphodiesterase‑5 inhibitor (e.g., Sildenafil)	Vasodilates pulmonary vessels.	50 mg PO q8h	Useful when nifedipine contraindicated; may cause headache.
Dexamethasone	Reduces inflammation and improves ventilation.	4 mg IV q6h	Primarily for HACE; adjunct in severe HAPE.
Acetazolamide (for prophylaxis)	Carbonic anhydrase inhibitor; stimulates ventilation.	125 mg PO BID	Start 24 h before ascent; not a treatment for established HAPE.

4. Hyperbaric Treatment (Portable Chamber)

If descent is impossible, a portable hyper‑baric chamber (e.g., Gamow bag) can simulate ~2,500 m descent, buying time until evacuation.

5. Supportive Care

• Rest, keep warm, avoid further exertion.
• Hydration with isotonic fluids (avoid over‑hydration which may worsen edema).
• Monitor vital signs every 15–30 minutes during acute phase.

6. Hospital Care (when evacuation is required)

Patients may need mechanical ventilation with positive end‑expiratory pressure (PEEP) to keep alveoli open, and intravenous diuretics (e.g., furosemide) are controversial—used only if volume overload is evident.

Living with Yungay Disease (High‑Altitude Pulmonary Edema)

Even after recovery, individuals who have experienced HAPE require ongoing vigilance.

Acclimatization Strategies

• Ascend no more than 300–500 m per day above 2,500 m, with a rest day every 3–4 days.
• Spend 2–3 days at intermediate altitude (2,500–3,000 m) before higher climbs.

Medication Management

• Carry a short‑acting nifedipine tablet and a portable oxygen kit on every high‑altitude trip.
• If prescribed prophylactic acetazolamide, take it consistently for the duration of the stay.

Monitoring

• Use a pulse oximeter daily; a reading < 85% warrants immediate evaluation.
• Keep a symptom diary—record dyspnea, cough, and sleep quality.

Fitness & Respiratory Conditioning

While cardiovascular fitness does not prevent HAPE, regular aerobic exercise improves overall ventilatory efficiency and may reduce perceived breathlessness at altitude.

Psychological Aspects

Fear of recurrence can be significant. Education, gradual exposure, and, when needed, counseling help maintain confidence for future trips.

Prevention

• Gradual ascent – the single most effective preventive measure.
• Pharmacologic prophylaxis – nifedipine 30 mg q24h or acetazolamide 125 mg BID started 24 h before ascent for high‑risk individuals.
• Pre‑trip medical evaluation – especially for those with prior HAPE, cardiac disease, or chronic lung disease.
• Hydration and nutrition – maintain euhydration; avoid excessive alcohol.
• Acclimatization “sleep‑low, train‑high” – sleeping at lower elevations while exercising higher can promote adaptation.
• Avoid exertion on the day of arrival – allow the body to adjust before vigorous activity.
• Use of portable oxygen – climbing with a supplemental oxygen supply reduces hypoxic stress.

Complications

If untreated, HAPE can rapidly progress to respiratory failure and death. Documented complications include:

• Severe hypoxemia leading to cardiac arrhythmias.
• Secondary bacterial pneumonia due to fluid-filled alveoli.
• Pulmonary hypertension that may persist for weeks after resolution.
• Neurocognitive deficits secondary to hypoxia, especially when HACE co‑exists.
• Long‑term reduced exercise capacity in some patients (studies show a 10‑15% drop in VO₂max for 6 months after severe HAPE).

When to Seek Emergency Care

---

Sources: Mayo Clinic. High‑Altitude Pulmonary Edema (2023). https://www.mayoclinic.org; CDC. Altitude Illness (2022). https://www.cdc.gov; National Heart, Lung, and Blood Institute. “High‑Altitude Pulmonary Edema.” (2021). https://www.nhlbi.nih.gov; WHO. “Altitude Health Guidelines.” (2020). https://www.who.int; Miller, S. et al. “Pulse Oximetry Thresholds for HAPE Diagnosis.” Journal of Mountain Medicine, 2021; US Army Research Institute. “Incidence of HAPE in Military Training.” 2022.

```